Patents Examined by Rachel M. Bennett
  • Methods of delivering materials into the skin, and compositions used therein
    Patent number: 6579516
    Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 17, 2003
    Inventor: Zahra Mansouri
  • Method for treating heart disease and cardiovascular disease in diabetic and non-diabetic patients
    Patent number: 6579531
    Abstract: The present invention is a system and method capable of improving the dietary fuel capabilities and diabetics impaired patients and correct an overutilization of free fatty acids associated with heart disease in diabetic and non-diabetic patients. The current invention is the treating of heart disease and cardiovasular disease using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve an increase dietary fuel capabilities and correct overutilization of free fatty acids associated with heart disease in both diabetic and non-diabetic patients.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 17, 2003
    Inventor: Thomas T. Aoki
  • Food bars containing nutritional supplements
    Patent number: 6576253
    Abstract: The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and/or minerals, DHA, one or more DHA taste-masking agents and, optionally, one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: June 10, 2003
    Assignee: PBM Pharmaceuticals, Inc.
    Inventors: Paul B. Manning, Jack H. Schramm, James W. McGrath, Jr.
  • Sustained-release form of administration containing tramadol saccharinate
    Patent number: 6576260
    Abstract: Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also contain tramadol in non-sustained release form, and other pharmaceutically acceptable excipients. Also disclosed are methods of preparation of and methods of treatment using the inventive formulations.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: June 10, 2003
    Assignee: Gruenenthal GmbH
    Inventors: Johannes Bartholomaeus, Heinrich Kugelmann, Iris Ziegler
  • Administration form comprising an acid-labile active compound
    Patent number: 6569453
    Abstract: An administration form for acid-labile active compounds are described. The administration forms have no enteric layers and are suitable for oral administration.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: May 27, 2003
    Assignee: Altana Pharma AG
    Inventors: Rudolf Linder, Rango Dietrich
  • Food bars containing nutritional supplements and anti-constipation and regularity maintaining-agents
    Patent number: 6569445
    Abstract: The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and/or minerals, and one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: May 27, 2003
    Assignee: PBM Pharmaceuticals, Inc.
    Inventors: Paul B. Manning, Jack H. Schramm, James W. McGrath, Jr.
  • Method of administration of paclitaxel-plasma protein formulation
    Patent number: 6569459
    Abstract: The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/&ggr;-globulin formulation.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: May 27, 2003
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventor: Moshe Flashner-Barak
  • Monomeric compositions effective as wound closure devices
    Patent number: 6565840
    Abstract: A biocompatible monomer composition includes: (A) at least one monomer, which forms a medically acceptable polymer; (B) at least one plasticizing agent present in the composition in an amount of from 0.5 wt. % to 15 wt. % of the composition; and (C) at least one acidic stabilizing agent having a pKa ionization constant of from about 1 to about 7. The composition can be applied to a variety of materials and is particularly suitable as in vivo tissue adhesive. A method of joining together in vivo two surfaces, e.g.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: May 20, 2003
    Assignee: Closure Medical Corporation
    Inventors: Jeffrey G. Clark, Jeffrey C. Leung
  • Artificial tear formulation
    Patent number: 6565861
    Abstract: Provided by the present invention are formulations suitable for application to mammalian eyes which contain a lipid binding protein and a polar lipid, present as a soluble complex in an aqueous electrolyte. The formulations described have shear-thinning (non-Newtonian viscosity) and surface tension properties to natural tears and are therefore useful as artificial tear substitutes for the treatment of dry eyes (e.g. keratoconjunctivitis sicca) and useful in ophthalmic applications in general.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: May 20, 2003
    Assignee: ISIS Innovation Limited
    Inventors: John Michael Tiffany, Beatrix Valeria Macey-Dare
  • Polymeric delivery formulations of leuprolide with improved efficacy
    Patent number: 6565874
    Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: May 20, 2003
    Assignee: Atrix Laboratories
    Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L Chandrashekar
  • Hair relaxer compositions utilizing complexing agent activators
    Patent number: 6562327
    Abstract: The present invention provides a composition for lanthionizing keratin fibers comprising at least one multivalent metal hydroxide and at least one complexing agent effective for dissociating said at least one multivalent metal hydroxide in sufficient quantity to effect lanthionization of said keratin fibers. In one embodiment, the complex that is formed between the complexing agent and a metal ion from the multivalent metal hydroxide is soluble in water. The invention is also drawn to a method for lanthionizing keratin fibers to achieve relaxation of the keratinous fibers.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: May 13, 2003
    Assignee: L'Oreal S.A.
    Inventors: Nghi Van Nguyen, David W. Cannell
  • Pheromone immobilized in stable hydrogel microbeads
    Patent number: 6562361
    Abstract: A microbead comprising pheromone encapsulated in a coacervate shell is provided. The coacervate shell is entrained in a hydrogel microbead without chemical crosslinking. The microbeads of the present invention are capable of dehydration and rehydration to release of pheromone to the intended environment.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 13, 2003
    Assignee: 3M Innovative Properties Company
    Inventor: Douglas Quong
  • Liquefied embolic materials capable of sol-gel phase transition and their use
    Patent number: 6562362
    Abstract: Disclosed are liquefied embolic materials capable of sol-gel phase transition in response to in vivo conditions, including temperature, ionic strength, and pH, and their uses. The liquefied embolic materials are made of copolymers based on temperature-sensitive isopropylacrylamide and ionic strength- and/or pH-sensitive monomers. In addition to finding excellent applications in the embolotherapy, the embolic materials can be used as extracellular matrixes for cell culture and for drug-delivery systems for cancer therapy.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: May 13, 2003
    Assignee: Kwangju Institute of Science and Technology
    Inventors: You Han Bae, Kun Na, Seong Il Kang, Jin Woo Yi, Moon Hee Han
  • High drug load immediate and modified release oral dosage formulations and processes for their manufacture
    Patent number: 6558699
    Abstract: This invention relates to high drug load granulation of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid in the anhydrous form, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: May 6, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Gopadi M. Venkatesh
  • Ocular tissue regeneration inducer
    Patent number: 6558688
    Abstract: The invention relates to an ocular tissue regeneration inducer which comprises, as an active ingredient, a hydrophilic polymer mainly composed of alkylene glycol units or vinyl monomeric units having a nondissociating hydrophilic group. The composition can induce the regeneration of ocular tissues such as the cornea, the crystalline lens, and the vitreous body.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: May 6, 2003
    Assignees: Kuraray Co., Ltd.
    Inventors: Mototsugu Saishin, Mitsuo Tsukamoto, Takashi Makabe, Yoshimi Kakimaru, Takumi Fujitani, Tatsuhiko Higaki
  • Control of intra-ocular pressure
    Patent number: 6548053
    Abstract: A method of reducing intra-ocular pressure (IOP) in a patient afflicted with elevated IOP is disclosed. The method comprises the step of administering (preferably topically to an afflicted eye) to the patient a therapeutically effective amount of a &bgr;-HSD-1 inhibitor.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: April 15, 2003
    Assignee: The University of Birmingham
    Inventors: Paul Michael Stewart, Philip Ian Murray
  • Periodic constriction of vessels to treat ischemic tissue
    Patent number: 6544543
    Abstract: Brief periods of occlusion of blood flow in an otherwise open target vessel adjacent to vessels supplying blood to an ischemic region are caused by periodic administration of a therapeutically effective amount of a vasoconstrictor. It is anticipated these brief periods of occlusion will induce the enlargement of collateral vessels, causing increased blood flow to the ischemic region.
    Type: Grant
    Filed: December 27, 2000
    Date of Patent: April 8, 2003
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Evgenia Mandrusov, Christopher J. Buchko, Wouter E. Roorda
  • Devices and compounds for treating arterial restenosis
    Patent number: 6544541
    Abstract: Described herein is the use of ADPRT decoy substrates to treat or prevent proliferative disorders. In one example, MIBG is shown to prevent restenosis in damaged vessels. In one embodiment, MIBG is combined with an adhesive agent for localizing the mixture to the site of injury. As a result of this arrangement, MIBG is not systemically released.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: April 8, 2003
    Assignee: Cardiovascular Solutions, Inc.
    Inventor: Peter Zahradka
  • Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis
    Patent number: 6544551
    Abstract: The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: April 8, 2003
    Assignee: Zentaris AG
    Inventors: Juergen Engel, Werner Sarlikiotis, Thomas Klenner, Peter Hilgard, Dieter Sauerbier, Eckhard Milsmann
  • Topical gel delivery system
    Patent number: 6517847
    Abstract: A composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition is a lotion that consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically acceptable base to adjust pH, (d) up to about 25% ww of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) an oil phase component and suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: February 11, 2003
    Assignee: Dow Pharmaceutical Sciences
    Inventors: Gordon J. Dow, Robert W. Lathrop, Debra A. Dow